Phase 3 Readout
NMRA: Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-3
June 11, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 11, 2026
- Company
- Neumora Therapeutics, Inc. (NMRA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-3
- Indication
- Major Depressive Disorder